Kirkland Advises Warburg Pincus and ARCHIMED on Sale of Polyplus
Kirkland & Ellis is advising co-controlling shareholders WP GG Holdings IV B.V., an affiliate of Warburg Pincus, and ARCHIMED on the sale of Polyplus for approximately €2.4 billion to Sartorius, a life science group. Polyplus was initially acquired by ARCHIMED in 2016, which sold half of its stake to Warburg Pincus in 2020. Polyplus is a global provider of upstream bioprocessing solutions, including transfection reagents and DNA plasmids, which are critical inputs used in the manufacturing of cell and gene therapies. Kirkland advised Warburg Pincus and Dechert advised ARCHIMED on the 2020 acquisition.
The Kirkland team is led by corporate partners Laurent Victor-Michel and Adrian Maguire and associates Guillaume Nivault, Etienne Vautier, Luke Forryan, Nikhil Mohindra and Lucy Bower; antitrust partners Marin Boney and Matthew Sinclair-Thomson and associate Miata Eggerly; and tax partners Nadine Gelli, Peter Abbott and Sonia Bouaffassa and associate Maria Clezy.
